Evaluation of RBS2418 in Patients with Advanced, Metastatic, and Progressive Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Metastatic Colorectal CancerAdvanced Colorectal Cancer
Interventions
DRUG

RBS2418

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.

DRUG

Placebo

Placebo to Match RBS2418

Trial Locations (3)

10000

RECRUITING

Tam Anh, Ha Noi General Hospital, Hanoi

70000

RECRUITING

Tam Anh TP. Ho Chi Minh General Hospital, Ho Chi Minh City

90095

NOT_YET_RECRUITING

University of California, Los Angeles, Los Angeles

All Listed Sponsors
collaborator

Tam Anh Research Institute

OTHER

lead

Riboscience, LLC.

INDUSTRY